Country Regulatory Filing Status Actions in ProgressNotes Australia Filed April 2015 Discussions indicate a possible approval in mid- 2016 Brazil Filed.

Slides:

Advertisements

Similar presentations

Working world wide against HIV for the health and human rights of men who have sex with men Working world wide against HIV for the health and human rights.

Advertisements

Brazil: from universal ARV access to universal HCV treatment? Juliana Vallini Friday, 23rd, July, 2010.

Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.

Introduction to Treat the Pain. The problem of unrelieved pain Globally, 7.3 million people die of cancer or HIV each year in moderate or severe pain.

Kat Smithson Policy and Campaigns Manager, NAT HIV prevention in England’s high prevalence local authorities: 2013/ /15 February 2015.

Welcome to the Business and Operational Planning for School-Based Health Centers RFP Workshop April 12, 2010.

Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.

XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

People left behind: People living with HIV

Can we prevent infection after an exposure

GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.

A very short introduction to patents & access to medicines.

Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.

REG set up: first steps… Alison Chisholm 7.40 am – 7:45 am.

HIV/AIDS in Prison Settings Dr. Monica Beg HIV/AIDS Unit, United Nations Office on Drugs and Crime, Krakow, Poland September 27, 2004.

1 AIDS 2010 Vienna, July 2010 HIV/AIDS and People from Countries where HIV is endemic – Black people of African and Caribbean descent living in Canada.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington.

Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.

ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

“Reaching across Arizona to provide comprehensive quality health care for those in need” Our first care is your health care Arizona Health Care Cost Containment.

Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.

Matthew Kavanagh Fighting AIDS in a Financial Crisis: We Can Do Better, More, Faster.

Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:

HIV and African M S M in England: A new wave of Challenge. Presented by Adebisi Alimi.

Female Condom Consortium Presentation by Yvonne Bogaarts World Population Foundation 25 October 2007 Reproductive Health Supplies Coalition SEMI-ANNUAL.

IAS Policy and Advocacy priority on Treatment as Prevention Carlos F. Cáceres Multidisciplinary Research on ARV-based Prevention 30 June 2013 Kuala Lumpur.

2004: 39.4 (35.9 – 44.3) million Western & Central Europe [ – ] North Africa & Middle East [ – 1.5 million] Sub-Saharan.

Treatment of AIDS in BRAZIL. ›Which nation has fared the best in response to the world’s Aids Epidemic? › It's not the United States; it's not China,

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

International AIDS Society’s Strategic Plan : Where are we up to? Rome, 19 July 2011.

Regional Videoconference Addressing Stigma and Discrimination of HIV/AIDS in Africa Thursday, April 2, 2009 UNAIDS Perspective Susan Timberlake, Senior.

The Global HIV/AIDS Epidemic Jennifer Kates, M.A., M.P.A. Vice President and Director, HIV Policy Kaiser Family Foundation KaiserEDU.org Tutorial April.

Where services are needed The number of people (both adults and children) living with HIV who are not receiving antiretroviral therapy.

HCT in the mining industry

South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.

GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.

 Drug Pricing and the Impact on Treatment Access - International Wim Vandevelde - European AIDS Treatment Group (EATG) 2010 HIV Research Catalyst Forum.

The Continuum of Participation in Research From HIV Prevention to Care: Seven Years of the iPrEx Trial Public Engagement with HIV Science.

Improving health in minority communities by…  Increasing access to both preventive medicine and the healthcare system  Distributing information about.

Industry: trends, concerns hopes and ideas VICH5 Conference Carel du Marchie Sarvaas, Executive Director October 2015.

Ethiopia Demographic and Health Survey 2011 HIV/AIDS Knowledge, Attitudes, and Behaviour.

Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.

2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.

The tipping point: When do placebos become unethical? Bridget Haire.

NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.

Expanded PrEP implementation across Australia Expanded implementation of PrEP across Australia 1.

Expanded PrEP implementation in NSW (EPIC-NSW) 1 AIDS 2016 | 22 July 2016.

1 Improving the agenda for SWITCH for nonprescription Medicines Sheila Kelly WSMI September 2015.

Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.

Perspectives from the MSM community in Asia on sexual pleasure and risk reduction 9th IAS Conference on HIV Science 25 July 2017 Paris, France Midnight,

BHIVA Satellite Symposium

HIV Post Exposure Prophylaxis

TransIT The Transgender Implementation Tool for the WHO key population guidelines.

9/17/2018 Meeting local HTA requirements Challenges for the Pharma HTA Statistician Marie-Ange PAGET Project Statistician – Lilly France EFSPI meeting.

Associação Brasileira de Paramiloidose

David Magnuson, Trevor Hawkins, Robertino Mera

Setting the Stage for PrEP Where are we now, and where should we go?

Contents - HIV global slides

Key issues in DOTS implementation

Median submission gap, median approval time and percentage approved as expedited for new active substances (NASs) approved by six authorities:

The Politics of PrEP The French Experience

Rollout time breakdown: 24 common NASs in 7 jurisdictions

Assessment routes and timelines in Australia (2011)

HIV infections newly diagnosed in injecting drug users and men who have sex with men, by country, and year of report, 2002– Injecting drug users.

Assessment routes and timelines

Reshmie Ramautarsing, M.D., Ph.D.

Presentation transcript:

Country Regulatory Filing Status Actions in ProgressNotes Australia Filed April 2015 Discussions indicate a possible approval in mid Brazil Filed September 2014 PrEP is being evaluated by the Brazilian drug regulatory authority. No timeline has been published Canada Filed summer 2015 Québec has developed guidelines for health care providers EuropeNo filing Gilead is in discussions with the European Medicines Agency re: regulatory filing for PrEP Gilead has provided data for assessment in France for PrEP that could result in temporary access or expanded access programs TAG: Truvada as PrEP: Select Global Regulatory Filings

Country Regulatory Filing Status Actions in ProgressNotes KenyaPending The Kenya National AIDS Control Council has included PrEP in its HIV Prevention Revolution Road Map This is only a recognition that PrEP is needed, not a step toward regulatory approval South Africa Filed November 2013; queries issued Q (addressed by Gilead) Both originator and generic manufacturers have submitted to the MCC and updated their submissions to include data from the IPERGAY and PROUD studies; however, the MCC has not indicated any specific timeline for review or approval Updates to the existing guidelines are in process; expansion to populations beyond men who have sex with men expected TAG: Truvada as PrEP: Select Global Regulatory Filings

Country Regulatory Filing Status Actions in ProgressNotes Thailand Filed May 2014; queries issued Q (addressed by Gilead) United States Approved July 2012 N/A Approved in July 2012 for prevention indication TAG: Truvada as PrEP: Select Global Regulatory Filings

Popular (Greek) narratives about PrEP

‘After chems comes condomless sex’

‘An observational study was enough to make gay men throw away condoms’

‘ Pharma tries to sell more medicines’

‘Pharma companies are happy with these campaigns. In the meantime, resistant gonorrhea is stronger than ever’

‘With all these a new mutation of the virus will come up’

‘It’s a new fad, saying “I am on PrEP”. I say “fuck off”’

Challenges for PrEP in Europe? Community acceptability surveys (e.g. in Pride events) Demonstration/Implementation studies (e.g. Amsterdam) A prevention indication is needed after a pediatric investigation plan (PIP) is carried out Generics Patent expiration and new formulation on the way (F/TDF  F/TAF)

Challenges for PrEP in Europe? Public budget (but until then…) Out of pocket (e.g. London) {will the right people get PrEP?} Buying from internet or pharma tourism {no prescription / no follow-up} PEP for PrEP

Apostolos Kalogiannis - Advocacy MA in Communication and Cultural Studies